P. Banks

发表

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study

P. Lapuerta, J. Kushner, M. Brandle, 2018, Diabetes Care.

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies

P. Lapuerta, H. Rodbard, J. Kushner, 2020, Diabetes Care.

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

P. Lapuerta, D. Powell, B. Zambrowicz, 2019, The Journal of clinical endocrinology and metabolism.

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment

P. Lapuerta, J. Rosenstock, G. Umpierrez, 2021, Diabetes, obesity & metabolism.

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

P. Lapuerta, J. Kushner, S. Garg, 2017, The New England journal of medicine.

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study

P. Lapuerta, J. Rosenstock, J. Kushner, 2018, Diabetes Care.

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, in Type 2 Diabetes on Metformin Monotherapy

P. Lapuerta, J. Rosenstock, W. Cefalu, 2014 .

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.

D. Powell, A. Sands, B. Zambrowicz, 2013, Clinical therapeutics.

Sotaglif lozin , a Dual SGLT 1 and SGLT 2 Inhibitor , as Adjunct Therapy to Insulin in Type 1 Diabetes

P. Lapuerta, J. Rosenstock, S. Garg, 2015 .

Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy

P. Lapuerta, J. Rosenstock, W. Cefalu, 2013, Clinical cardiology.

Efficacy and safety of telotristat ethyl in patients With carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period.

P. Lapuerta, D. Hörsch, M. Pavel, 2017 .

Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome

P. Lapuerta, M. Pavel, J. Ramage, 2019, Journal of Patient-Reported Outcomes.

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.

P. Lapuerta, James C Yao, A. Sands, 2014, Endocrine-related cancer.

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

P. Lapuerta, D. Hörsch, M. Pavel, 2020, Journal of Gastrointestinal Cancer.

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study

E. Ferrannini, D. Powell, P. Banks, 2022, Diabetes care.

Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.

R. Wadwa, J. Kushner, T. Danne, 2020, Diabetes technology & therapeutics.

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial

J. Kushner, T. Danne, D. McGuire, 2019, Diabetes, obesity & metabolism.

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

P. Lapuerta, J. Rosenstock, S. Garg, 2015, Diabetes Care.

Recruitment into a Long‐Term Pediatric Asthma Study During Emergency Department Visits

D. Jaffe, R. Strunk, P. Banks, 2004, The Journal of asthma : official journal of the Association for the Care of Asthma.

LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.

Alan G. E. Wilson, P. Lapuerta, D. Powell, 2015, Clinical therapeutics.

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

P. Lapuerta, D. Hörsch, M. Pavel, 2021, Neuroendocrinology.

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Alan G. E. Wilson, N. C. Goodwin, F. Mseeh, 2012, Clinical pharmacology and therapeutics.

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy

P. Lapuerta, J. Rosenstock, W. Cefalu, 2014, Diabetes Care.

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

Z. Ding, D. Powell, A. Sands, 2013, Clinical therapeutics.

Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.

P. Lapuerta, T. Seufferlein, B. Wiedenmann, 2015, The Journal of clinical endocrinology and metabolism.

Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure

Deepak L. Bhatt, P. Ponikowski, Lawrence A Leiter, 2021, Annals of Internal Medicine.

Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study.

B. Zambrowicz, P. Banks, M. Kulke, 2012, Journal of Clinical Oncology.

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program

J. Rosenstock, J. Kushner, S. Garg, 2019, Diabetes Care.

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease

J. Rosenstock, G. Umpierrez, E. Ferrannini, 2023, Diabetes, obesity & metabolism.

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Kjell Öberg, P. Lapuerta, A. Sands, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)

P. Lapuerta, J. Rosenstock, J. Kushner, 2018, Diabetes.

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study)

P. Lapuerta, J. Kushner, T. Danne, 2018, Diabetes.

Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes

P. Rossing, F. Persson, P. Banks, 2023, Diabetes, obesity & metabolism.